Labcorp Holdings (LH) has agreed to acquire certain assets of OPKO Health's (OPK) BioReference Health unit for up to $225 million, the companies said Tuesday.
The purchase price includes $192.5 million payable at closing and up to $32.5 million in earnout payments based on performance, the companies said.
Under the deal, Labcorp will acquire BioReference Health's oncology-related laboratory testing businesses and clinical testing services in the US, along with certain customer accounts and other operating assets, the companies said.
The assets being acquired currently generate about $85 million to $100 million in annual revenue and Labcorp said it expects the acquisition to be accretive to earnings in the first year.
The transaction is expected to close in the second half of 2025, the companies said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。